Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Kaly Needs To Address Another BillionDollar Potential Market

<< Previous

Bullboard Posts

Next >>

Comment by AngelaLon Apr 26, 2021 6:38pm

91 Views

Post# 33071666

RE:Kaly Needs To Address Another BillionDollar Potential Market

No, this is not how drug development works. R-107 successfully transited formal ("GLP") toxicology studies in rats and dogs. Such studies require the testing of doses many times in excess of the intended therapeutic dose in order to ascertain the NOAEL (no observed adverse event level). So, R-107 is safe at massive doses by definition for it to have come this far.

<< Previous

Bullboard Posts

Next >>

Canadian government to fund Electric Royalties portfolio property